Sacral Nerve Modulation in Multiple Sclerosis

  • Research type

    Research Study

  • Full title

    SACRAL NERVE MODULATION AS A TREATMENT FOR VOIDING DYSFUNCTION IN MULTIPLE SCLEROSIS PATIENTS

  • IRAS ID

    337422

  • Contact name

    Mahreen Pakzad

  • Contact email

    mahreen.pakzad@nhs.net

  • Sponsor organisation

    Academisch ziekenhuis Maastricht

  • Clinicaltrials.gov Identifier

    NL86741.000.24, Central Committee on Research Involving Human Subjects (CCMO)

  • Duration of Study in the UK

    3 years, 1 months, 31 days

  • Research summary

    Sacral Nerve Modulation (SNM) is a NICE approved treatment for severe urgency and frequency, urgency incontinence and non-obstructive retention who have failed or could not tolerate conservative treatments. Previously, SNM devices were not MRI compatible and as patients with MS require MRIs periodically, this was not an appropriate treatment approach. After the recent development of MRI compatible technology this should no longer be an obstacle. Recent studies have shown a promising effect of SNM in MS patients, however there is a lack of large randomised homogeneous studies to better demonstrate the benefit of this therapy in this specific cohort of patients. This is a multi-centre, multinational Randomised Control Trial (RCT) to investigate the effects of SNM in MS patients whom are suffering from neurological lower urinary tract dysfunction (nLUTD). Included participants will be followed for 12 months after the device is activated. Two groups will be randomly allocated. Both groups will receive a SNM device after a successful testing phase. In the intervention group the device will be activated immediately after implantation and followed up at three month intervals, the control group will not receive stimulation for the first three months where after which stimulation will be started. Patients and implanting surgeons will be blinded to allocation of immediate versus delayed activation.
    Both groups will be followed up with bladder diaries and quality of life questionnaires, as is standard of care. Patients will remain under follow up for 12 months.This study will help disseminate the benefits of SNM to patients with Multiple sclerosis.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    25/WM/0204

  • Date of REC Opinion

    20 Nov 2025

  • REC opinion

    Further Information Favourable Opinion